News organisations gather in Paris to collaborate on securing media provenance
It has never been more important to safeguard authentic news media, say the organisers.
Seoul (AFP) | 12/02/2026 - 22:43:13 | N. Korea warns of 'terrible response' in event of repeat drone incursion from South: KCNA
Santo Domingo (AFP) | 12/02/2026 - 21:36:05 | US shutters its Dominican anti-drug office over corruption claims
Washington (AFP) | 12/02/2026 - 21:33:06 | Obama says Trump climate repeal leaves Americans 'less safe, less healthy'
Caracas (AFP) | 12/02/2026 - 21:04:21 | Venezuela postpones adoption of landmark amnesty bill: AFP
San Francisco (AFP) | 12/02/2026 - 20:47:18 | Anthropic raises $30 bn, valuing OpenAI rival at $380 bn
San Francisco (AFP) | 12/02/2026 - 20:23:15 | Anthropic raises $30 bn, valuing OpenAI rival at $380 bn
Washington (AFP) | 12/02/2026 - 20:10:08 | Trump says failure to make deal will be 'very traumatic' for Iran
Alden Biesen (AFP) | 12/02/2026 - 20:08:09 | Germany's Merz says shared EU debt only for 'exceptional situations'
Washington (AFP) | 12/02/2026 - 19:54:44 | Trump says 'terminating' green vehicle emissions rules
Washington (AFP) | 12/02/2026 - 19:43:01 | Trump announces formal repeal of legal basis for US climate rules
It has never been more important to safeguard authentic news media, say the organisers.
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for p...
Long-term global partnership continues to provide newsrooms around the world with unrivalled visual coverage of news, sport and entertainment.
Agence France-Presse (AFP) is pleased to announce a new partnership with Alliance magazine, a leading global media platform serving decision-makers in the philanthropic sector.
Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215203213/en/Ant Group’s AI health app AQ features three core capabilities: health Q&A, AI health companion, and integrated health services. The upgraded ...
Copeland and Daikin, two global leaders in heating, ventilation and air conditioning (HVAC) solutions, today announced the expansion of their existing joint venture into Europe. Through this cooperation, the companies will introduce advanced inverter swing rotary compressors, power electronics and controls designed specifically for European residential heat pumps. This collaboration underscores both companies’ commitment to accelerate the energy transition, with heat pumps recognized by industr...
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay conclu...
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I ...
Starting date: November 1, 2025
Deadline for applications: September 1, 2025
Location: Los Angeles - North America region
THE JOB